Toggle Main Menu Toggle Search

Open Access padlockePrints

Cereblon vs VHL: Hijacking E3 Ligases Against Each Other Using PROTACs.

Lookup NU author(s): Dr Chiara ManiaciORCiD

Downloads


Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


Abstract

The von Hippel-Lindau (VHL) and cereblon (CRBN) proteins are substrate recognition subunits of two ubiquitously expressed and biologically important Cullin RING E3 ubiquitin ligase complexes. VHL and CRBN are also the two most popular E3 ligases being recruited by bifunctional Proteolysis-targeting chimeras (PROTACs) to induce ubiquitination and subsequent proteasomal degradation of a target protein. Using homo-PROTACs, VHL and CRBN have been independently dimerized to induce their own degradation. Here we report the design, synthesis and cellular activity of VHL-CRBN hetero-dimerizing PROTACs featuring diverse conjugation patterns. We found that the most active compound 14a induced potent, rapid and profound preferential degradation of CRBN over VHL in cancer cell lines. At lower concentrations, weaker degradation of VHL was instead observed. This work demonstrates proof of concept of designing PROTACs to hijack different E3 ligases against each other, and highlights a powerful and generalizable proximity-induced strategy to achieve E3 ligase knockdown.


Publication metadata

Author(s): Girardini M, Maniaci C, Hughes SJ, Testa A, Ciulli A

Publication type: Article

Publication status: Published

Journal: Bioorganic & Medicinal Chemistry

Year: 2019

Volume: 27

Issue: 12

Pages: 2466-2479

Print publication date: 15/06/2019

Online publication date: 22/02/2019

Acceptance date: 21/02/2019

Date deposited: 22/02/2021

ISSN (print): 0968-0896

ISSN (electronic): 1464-3391

Publisher: Elsevier Ltd

URL: https://doi.org/10.1016/j.bmc.2019.02.048

DOI: 10.1021/acschembio.8b01016


Altmetrics

Altmetrics provided by Altmetric


Funding

Funder referenceFunder name
Drug discovery activities were supported by Wellcome Trust strategic awards to Dundee (094090/Z/10/Z).
European Research Council (ERC) under the European Union’s Seventh Framework Programme (FP7/2007 − 2013) as a Starting Grant to A.C. (grant agreement no. ERC-2012-StG-311460 DrugE3CRLs).
M.G. and C.M. were funded by PhD Studentships from the Italian Ministry of Education, University and Research (Miur).

Share